LEIGH BETH BROWN: Open Payments
NPI 1689281685 · OXFORD, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,606 in 114 payments from 23 companies in 2025. Trend: 2023 $1,737 · 2024 $2,020 · 2025 $2,606
Food & beverage: $2,517Education: $89
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $326 |
| Janssen Biotech, Inc. | 12 | $312 |
| GENZYME CORPORATION | 11 | $311 |
| Madrigal Pharmaceuticals | 8 | $310 |
| PFIZER INC. | 6 | $173 |
| Gilead Sciences, Inc. | 9 | $167 |
| Lilly USA, LLC | 7 | $150 |
| Enterra Medical, Inc. | 1 | $128 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $118 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $118 |
Products named: DUPIXENT, TREMFYA, REZDIFFRA, VELSIPITY, RINVOQ, OMVOH, XIFAXAN, LINZESS.
Industry payments across MS — which companies pay providers there.
